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Agonist-induced reduction in both the number of ml muscarinic receptors and the mRNA coding for the receptor protein was investigated in 
Chinese hamster ovary (CHO) cells which were transfected with the ml muscarinic receptor gene. Receptor concentration was measured by the 
specific binding of the muscarinic ligand, PHlquinuclidinyl benzilate (PHIQNB), and Northern blot hybridization analysis was used to evaluate 
the levels of receptor mRNA. Incubation of cells with 1 mM of the muscarinic agonist, carbamylcholine (CBC), for 24 h decreased receptor density 
and mRNA levels in cells by 65% and 73%, respectively. These results indicate that agonist-induced down-regulation of ml muscarinic receptors 
might be due to, at least in part, a decrease in receptor synthesis resulting from a reduction in the steady-state level of their mRNA. 
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1. INTRODUCTION 
Desensitization and/or down-regulation of G 
protein-coupled receptors is a common phenomenon 
observed in a variety of cell types upon prolonged 
stimulation by receptor agonists [l]. Muscarinic recep- 
tors, which are members of this superfamily, have been 
shown to be regulated in a similar fashion [2-61. 
However, the molecular basis for agonist-induced 
reduction in the number and the sensitivity of musca- 
rinic receptors remains unclear. Although it has been 
suggested that muscarinic receptor down-regulation is 
due to an increase in the rate of receptor protein 
degradation [7], there have been no attempts to assess 
alterations in receptor biosynthesis. An important ques- 
tion to be addressed in this regard is whether prolonged 
muscarinic receptor activation alters the concentration 
of mRNA coding for the receptor, similar to what has 
been shown recently in the case of &adrenergic recep- 
tors [8]. There are currently five known subtypes of 
muscarinic receptors [9]. The ml muscarinic receptor 
subtype is of a particular importance, since it is abun- 
dant in brain regions which are closely associated with 
memory and cognition [9]. Since memory deficits are 
treated on a long-term basis with either directly acting 
muscarinic agonists or acetylcholinesterase inhibitors 
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[9], it is therefore important to investigate the 
mechanisms underlying regulation of ml receptors. Un- 
fortunately, however, there are no known established 
cell lines which express this subtype of muscarinic 
receptors. Therefore, we have employed Chinese 
hamster ovary (CHO) cells which were stably 
transfected with the ml muscarinic receptor gene [lo] 
for this purpose. Here, we report for the first time that 
agonist-induced down-regulation of ml muscarinic 
receptors is associated with a similar decrease in the 
steady-state level of the specific mRNA encoding this 
receptor protein. 
2. MATERIALS AND METHODS 
2.1. Cell culture 
Chinese hamster ovary (CHO) cells stably transfected with the rat 
ml muscarinic receptor gene (SmaI 1.73 kb restriction fragment of 
genomic clone ~71 [lo] containing the entire coding region of 1.38 kb) 
were provided by Drs J.C. Venter and CM. Fraser at the National In- 
stitutes of Health [ll]. Cells were grown in tissue culture flask (75 
cm*/250 ml) in 20 ml of DMEM 199 supplemented with 10% (v/v) 
bovine calf serum and 0.005% (w/v) geneticin. Cells were grown at 
37°C in a humidified atmosphere consisting of COz/air (1: 9). In all 
experiments, cells were used after 6 days from subculture. 
2.2. Preparation of mRNA and Northern blot analysis 
Total cellular RNA was extracted by the guanidinium thiocyanate 
method [12]. Poly(A)+ RNA used in Northern blot analysis was 
isolated by oligo (dT)-cellulose [13]. Samples of poly(A)+ RNA 
(lo-2Opg) were denatured with 50% formamide and electrophoresed 
through 1 .O% agarose/0.66 M formaldehyde gels [13], then transfer- 
red to nitrocellulose membranes (Optibind, Schleicher & Schuell, 
Keene, NH). Blots were hybridized using a 0.39 kb PstI/NindIII 
restriction fragment of the rat ml muscarinic receptor cDNA cor- 
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Fig. 1. Saturation isotherm of specific [‘HIQNB binding in control 
and desensitized ml CHO cells. Cells were incubated in monolayer 
with or without (control) 1 mM CBC for 24 h at 37”C, then washed 
and harvested. Intact cells (0.21 kO.03 mg protein for control and 
0.18 f 0.03 mg protein for CBC group) were incubated with increas- 
ing concentrations of [‘HIQNB for 60 min at 37°C followed by filtra- 
tion as described in section 2. Nonspecific binding was determined in 
the presence of 1OpM atropine and subtracted from all values. Data 
are shown as the mean + SE from three independent experiments per- 
formed in triplicate. 
responding to bases number 672-1044 of the sequence [14] (kindly 
provided by Dr T.I. Bonner, National Institutes of Health). The pro- 
be was -labeled with [m-‘*P]dCTP using a random priming labeling kit 
(Pharmacia, Piscataway, NJ). Hybridization was performed with 
1-3x 10-6 cpm/ml of the probe at 42°C for 18 h in 3xSSC 
(1 x SSC = 0.15 M NaC110.015 M Na-citrate, pH 7.0) containing 40% 
formamide, 10% dextran, 1 ~Denhardt’s solution and 20 /g/ml 
denatured salmon sperm DNA. Blots were washed successively in 
1 x SSC/O. 1% SDS (2 x 20 min at room temperature and 20 min at 
55”C), 0.1 x SSC/O.l% SDS (20 min at 55°C and 15 min at 6O’C) and 
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Fig. 2. Northern blot analysis of mRNA in control and desensitized 
ml CHO cells. Hybridization with “P-labeled ml muscarinic recep- 
tor probe in control cells and in cells which were incubated with 1 mM 
CBC for 24 h at 37°C (CBC group). In this particular experiment, 
densitometric scanning of the summation of the three bands yielded 
a ratio of 5.7 when control cells were compared to densensitized cells. 
Hybridization of the same blot after removal of the ml probe with a 
‘*P-labeledfl-actin probe resulted in the detection of a single band and 
indicated that the amount of loaded mRNA in the control group was 
1.4 times larger than that of the CBC group. 18s and 28s mark the 
position of the corresponding ribosomal RNA species. 
3 X SSC/O.l% SDS (10 min at 65”(Z), and exposed to X-ray film with 
intensifying screens for 24-34 h at - 7O’C. The ml receptor probe was 
then removed and the blots were hybridized under the same condi- 
tions with a 0.77 kb ‘*P-labeled chicken&actin cDNA probe (Oncor, 
Gaithersburg, MD; 1-3x 10m6 cpm/ml) followed by washing to a 
final stringency of 0.1 x SSC/O. 1% SDS (2 x 20 min at 65°C) and ex- 
posure to X-ray film for 12-20 h. Autoradiograms were scanned by 
a densitometer (Hoefer, San Francisco, CA) and the hybridization 
signals of the ml receptor probe were expressed as a ratio of the cor- 
responding signals of the ,f3-actin probe to account for differences in 
loading or transfer. Molecular weights were determined using RNA 
molecular weight markers (BRL, Gaithersburg, MD). 
2.3. Muscarinic receptor binding assay 
Suspended intact cells were incubated with [3H]quinuclidinyl ben- 
zilate ([3H]QNB) (32.9 Ci/mmol, NEN Research Products, Boston, 
MA) in a concentration range of 0.01-0.7 nM in a final volume of 1 
ml of oxygenated Krebs-Henseleit buffer. Nonspecific binding was 
measured in the presence of 10 pM atropine. After 1 h at 37°C 
samples were filtered under vacuum through Whatman glass fiber 
GF/B filters, followed by washing 3 times with ice-cold 0.9% NaCl 
solution. Radioactivity was measured after 6 h of the addition of scin- 
tillation fluid by liquid scintillation spectrometry. Saturation 
isotherms of specific binding were analyzed by Scatchard plots [15] 
using linear least-squares regression and protein was assayed accor- 
ding to the method of Lowry et al. [16] using bovine serum albumin 
as a standard. 
3. RESULTS AND DISCUSSION 
Binding studies using the specific muscarinic receptor 
ligand [3H]QNB in intact CHO cells transfected with 
the ml muscarinic receptor gene showed saturable and 
high affinity binding (B,,, = 427.1+ 55.1 fmol/mg pro- 
tein, Kd = 41 .O t 5.7 PM) (Fig. 1). Incubation of cells in 
monolayer with a receptor-saturating concentration (1 
mM) of carbamylcholine (CBC) for 24 h at 37°C 
resulted in a significant (PcO.05) decline in B,,, of 
[3H]QNB to 147.4k29.4 fmol/mg protein, without a 
significant change in the Kd (30.6k8.6 PM) (Fig. 1). 
The absence of changes in Kd suggests that the observed 
reduction in binding is not due to the presence of 
residual CBC in the binding assay. Thus, agonist treat- 
ment reduced receptor concentration by 66 + 6% (mean 
+ S.E.M.). These data are similar to those obtained in 
other cell lines [3-61 and primary tissues [17]. The 
decrease in receptor density by 1 mM CBC was time 
dependent, with a half-maximal effect of 15 h. It was 
also dependent on the concentration of CBC (EC50 = 1 
PM) when cells were desensitized for 24 h (data not 
shown). The presence of 10pM atropine during incuba- 
tion of cells with 1 mM CBC for 24 h completely 
abolished CBC-induced receptor down-regulation 
(135% of control; J. Hu, S.-Z. Wang and E.E. El- 
Fakahany, manuscript in preparation). Taken together, 
these data suggest hat this effect of CBC is associated 
specifically with its activation of muscarinic receptors. 
Northern blot hybridization using a 32P-labeled 
specific cDNA probe for ml muscarinic receptors 
detected three distinct mRNA species with molecular 
weights of 2.2 (corresponding to the mol. wt. of the 
transfected fragment), 3.0 and 3.4 kb (Fig. 2), while 
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Fig. 3. Comparison between CBC-induced receptor down-regulation 
and decrease in ml mRNA. The data shown were derived from the ex- 
periments presented in Figs 1 and 2, where control is the correspon- 
ding value in cells which were not treated with CBC. Receptor density 
is presented as the B,, of [‘HIQNB binding. mRNA levels were 
calculated by densitometric scanning of the three bands which 
hybridized with the ml probe (see Fig. 2) after correction for the in- 
tensity of hybridization of the @actin probe for each sample. The 
data shown are the means + SE for three independent experiments. 
hybridization with a @actin probe demonstrated the 
presence of a single molecular weight mRNA (not 
shown). The reasons for the appearance of these multi- 
ple bands are not clear, and it is not possible to provide 
a conclusive explanation for this phenomenon at pre- 
sent. However, all three bands are most likely related to 
a specific hybridization signal, particularly since the 
probe was homogeneous (data not shown) and the 
hybridization conditions were relatively stringent. Fur- 
thermore, screening of an EMBL database indicated 
that there is no more than 52% homology with any of 
24 000 non-muscarinic receptor cloned sequences (also 
see below). Thus, the observed multiple bands might 
reflect different degrees of processing of the ml recep- 
tor mRNA resulting from the stable transfection of the 
foreign muscarinic receptor gene into the genome, 
perhaps in multiple copies per genome. 
Incubation of cells in monolayer with 1 mM CBC for 
24 h at 37’C resulted in reducing the level of mRNA en- 
coding ml muscarinic receptors by 73 + 5% (Figs 2 and 
3). This reduction was observed for all the three 
hybridizable mRNA species to a similar extent, suppor- 
ting the notion that they all correspond to an ml recep- 
tor transcript. Possible differences in the amount of 
loaded mRNA between control and treated cells or dif- 
ferences in the efficiency of mRNA transfer could not 
account for the observed decrease in mRNA hybridiza- 
tion, since all data were corrected for the hybridization 
of a&actin probe to the same blots. Similar results have 
been published recently where incubation with iso- 
proterenol resulted in a decrease in mRNA encoding ,& 
adrenergic receptors in Chinese hamster fibroblasts 
[ 181, DDTi MF-2 hamster vas deferens cells [8] and S49 
mouse lymphoma cells [19]. In the presence of 10 PM 
atropine, the magnitude of the reduction of ml mRNA 
concentration by CBC was attenuated from 73% to 
27% (n = 2, data not shown), suggesting that the effects 
of CBC are mediated by activation of muscarinic recep- 
tors. It is noteworthy that in the present study there was 
an excellent correspondence in the magnitude of 
agonist-induced receptor down-regulation and the 
observed decrease in ml receptor mRNA after desen- 
sitization with 1 mM CBC for 24 h (Fig. 3). Preliminary 
experiments howed that this correlation between the 
decrease in mRNA and receptor down-regulation holds 
at shorter time points. Thus, there was a decrease in the 
concentration of ml receptor mRNA of 15% and 34% 
after incubation of cells with 1 mM CBC for 6 and 12 
h, respectively, which is in reasonable agreement with 
the observed 18% and 58% decrease in receptor density 
at the same time points (n=2, data not shown). 
Moreover, the two parameters were reduced by approx- 
imately 50% at 1 ,uM CBC for 24 h (47% and 55% 
reduction in mRNA and B,,,,,, respectively, n = 2, data 
not shown). These data suggest that the lowered steady- 
state level of muscarinic receptors following prolonged 
treatment with agonist is not solely the result of an in- 
crease in the rate of receptor degradation as has been 
suggested previously [7], but could also result from a 
decrease in receptor protein synthesis as a consequence 
of a decrease in the level of its mRNA. These data also 
suggest hat the transcription regulatory elements which 
influence the concentration of mRNA might reside on 
or near the receptor coding region. The ml receptor 
gene construct used for transfecting CHO cells contains 
0.14 and 0.21 kb of untranslated sequences at the 5’ 
and 3’ end, respectively. Careful analysis of the 
upstream untranslated sequence should provide 
valuable information regarding the existence and 
localization of such regulatory elements. Future studies 
should aim at determining whether the observed 
decrease in the steady-state level of ml muscarinic 
receptor mRNA is due to a decrease in the rate of 
transcription, a decrease in the stability of mRNA or a 
combination of both. The possible role of muscarinic 
receptor-induced second messenger signals in the 
observed effects should also be investigated. 
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